论文部分内容阅读
[目的]观察双铂方案二线治疗复发转移食管癌的近期疗效及不良反应。[方法]30例一线化疗后复发转移食管癌患者,进行二线治疗,化疗方案:顺铂25mg/m2d1,奈达铂25mg/m2d2,3,氟尿嘧啶0.35g/m2civ d1~7,3周重复。[结果 ]部分缓解(PR)11例,疾病稳定(SD)8例,疾病进展(PD)11例,有效率(RR)为36.7%,疾病控制率(DCR)为63.3%,中位达进展时间(TTP)为4.3个月(95%CI:1.1~10.5),中位生存时间(MST)为8.9个月(95%CI:2.1~15.3)。主要不良反应为血液学毒性,Ⅲ~Ⅳ级白细胞减少的发生率分别为13.3%,Ⅲ级口腔炎的发生率为6.7%。[结论]双铂联合氟尿嘧啶二线治疗复发转移食管癌的近期疗效较好,不良反应可耐受。
[Objective] To observe the short-term curative effect and adverse reactions of second platinum regimen in the treatment of recurrent esophageal cancer. [Method] Thirty patients with recurrent and metastatic esophageal cancer after first-line chemotherapy were treated with second-line chemotherapy. The chemotherapy regimens were repeated with cisplatin 25mg / m2d1, nedaplatin 25mg / m2d2,3 and fluorouracil 0.35g / m2civ d1-7. [Results] Eleven cases of partial remission (PR), 8 cases of stable disease (SD) and 11 cases of disease progression (PD) showed an effective rate (RR) of 36.7% and a disease control rate (DCR) of 63.3% The median time to survival (TTP) was 4.3 months (95% CI: 1.1 to 10.5) and the median survival time (MST) was 8.9 months (95% CI: 2.1 to 15.3). The main adverse reactions were hematological toxicity, the incidence of grade Ⅲ ~ Ⅳ leukopenia was 13.3%, and the incidence of grade Ⅲ stomatitis was 6.7%. [Conclusion] The double-platinum plus fluorouracil second-line treatment of recurrent esophageal cancer recurrence is good, adverse reactions can be tolerated.